Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.

View Full Paper
Ask AI
Bookmark
Share

Authors

QCQing CaoCMCameron McDonald-HymanJMJoseph Maakaron

Discussion

Loading...

Member takes

Overview

Nonmyeloablative transplant shows low non-relapse mortality in hematological malignancies, suggesting effective GVHD prophylaxis.

Key Points

  • The aim is to evaluate the outcomes of allogeneic hematopoietic stem cell transplantation using nonmyeloablative conditioning.
  • 133 patients received allo-HSCT with NMA conditioning (Flu/Cy/2Gy TBI) and PTCy-based GVHD prophylaxis.
  • Non-relapse mortality, overall survival, and graft-versus-host disease incidences were assessed post-transplant.
  • Endpoints included relapse-free survival and chronic GVHD over a 2-year period.
  • The total non-relapse mortality was 3.7% with a median time to NRM of 51 days.
  • Overall survival was 75% with a median survival of 371 days.
  • The incidence of chronic GVHD was 13%, while acute GVHD grade II-IV was noted at 17%.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d874https://doi.org/10.1182/blood-2025-4220
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis2025
  2. 2An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.2025
  3. 3T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT2025
  4. 4Outcomes of myeloablative vs reduced and non-myeloablative conditioning in MRD-negative AML and ALL with ptcy-based GVHD prophylaxis2025
  5. 5Effect of post-transplant cyclophosphamide on outcomes in stem cell transplant recipients with myelofibrosis2025